The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study
Background Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy...
Saved in:
| Published in | BMC urology Vol. 22; no. 1; pp. 19 - 10 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
12.02.2022
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-2490 1471-2490 |
| DOI | 10.1186/s12894-022-00974-0 |
Cover
| Abstract | Background
Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP).
Methods
In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019–Feb2021—Institutional ethics committee STS CE Lazio approval no.1/N-726—ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® (“controls”). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture.
Results
111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (
p
= 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3–11] versus 10 [5–13], Group A vs B, respectively,
p
= 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different.
Conclusions
The present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively.
Trial registration
The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021—Registration number NCT05130918. |
|---|---|
| AbstractList | Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP).
In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019-Feb2021-Institutional ethics committee STS CE Lazio approval no.1/N-726-ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® ("controls"). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture.
111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3-11] versus 10 [5-13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different.
The present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively.
The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021-Registration number NCT05130918. Background Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase[R]) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP). Methods In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019-Feb2021--Institutional ethics committee STS CE Lazio approval no.1/N-726--ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase[R] suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase[R] ("controls"). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture. Results 111 patients were randomized: 56 in Group A received Mictalase[R]. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3-11] versus 10 [5-13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different. Conclusions The present randomized trial investigated the efficacy of Mictalase[R] in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase[R]. Lower rate of positive urine culture favored Mictalase[R] group 15-days postoperatively. Trial registration The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021--Registration number NCT05130918. Keywords: Benign prostatic hyperplasia, BPH, Laser enucleation, ThuLEP, LUTS, Urinary tract infections Background Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP). Methods In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019–Feb2021—Institutional ethics committee STS CE Lazio approval no.1/N-726—ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® (“controls”). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture. Results 111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3–11] versus 10 [5–13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different. Conclusions The present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively. Trial registration The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021—Registration number NCT05130918. Abstract Background Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP). Methods In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019–Feb2021—Institutional ethics committee STS CE Lazio approval no.1/N-726—ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® (“controls”). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture. Results 111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3–11] versus 10 [5–13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different. Conclusions The present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively. Trial registration The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021—Registration number NCT05130918. Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP).BACKGROUNDSeveral studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP).In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019-Feb2021-Institutional ethics committee STS CE Lazio approval no.1/N-726-ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® ("controls"). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture.METHODSIn this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019-Feb2021-Institutional ethics committee STS CE Lazio approval no.1/N-726-ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® ("controls"). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture.111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3-11] versus 10 [5-13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different.RESULTS111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3-11] versus 10 [5-13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different.The present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively.CONCLUSIONSThe present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively.The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021-Registration number NCT05130918.TRIAL REGISTRATIONThe clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021-Registration number NCT05130918. Background Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP). Methods In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019–Feb2021—Institutional ethics committee STS CE Lazio approval no.1/N-726—ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® (“controls”). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture. Results 111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A ( p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3–11] versus 10 [5–13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different. Conclusions The present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively. Trial registration The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021—Registration number NCT05130918. Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase[R]) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP). In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019-Feb2021--Institutional ethics committee STS CE Lazio approval no.1/N-726--ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase[R] suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase[R] ("controls"). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture. 111 patients were randomized: 56 in Group A received Mictalase[R]. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3-11] versus 10 [5-13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different. The present randomized trial investigated the efficacy of Mictalase[R] in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase[R]. Lower rate of positive urine culture favored Mictalase[R] group 15-days postoperatively. |
| ArticleNumber | 19 |
| Audience | Academic |
| Author | Bertolo, Riccardo Maiorino, Francesco Antonucci, Michele Bove, Pierluigi Cipriani, Chiara Iacovelli, Valerio Carilli, Marco Ganini, Carlo Vittori, Matteo Signoretti, Marta Petta, Filomena Panei, Massimo |
| Author_xml | – sequence: 1 givenname: Riccardo surname: Bertolo fullname: Bertolo, Riccardo email: riccardobertolo@hotmail.it organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research – sequence: 2 givenname: Chiara surname: Cipriani fullname: Cipriani, Chiara organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research – sequence: 3 givenname: Matteo surname: Vittori fullname: Vittori, Matteo organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research – sequence: 4 givenname: Marco surname: Carilli fullname: Carilli, Marco organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research, Urology Unit, Department of Surgery, Tor Vergata University of Rome – sequence: 5 givenname: Francesco surname: Maiorino fullname: Maiorino, Francesco organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research – sequence: 6 givenname: Valerio surname: Iacovelli fullname: Iacovelli, Valerio organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research – sequence: 7 givenname: Carlo surname: Ganini fullname: Ganini, Carlo organization: Torvergata Oncoscience Research TOR, Department of Experimental Medicine, University of Rome Tor Vergata – sequence: 8 givenname: Michele surname: Antonucci fullname: Antonucci, Michele organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research – sequence: 9 givenname: Marta surname: Signoretti fullname: Signoretti, Marta organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research, Urology Unit, Department of Life, Health and Environmental Sciences, University of L’Aquila – sequence: 10 givenname: Filomena surname: Petta fullname: Petta, Filomena organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research – sequence: 11 givenname: Massimo surname: Panei fullname: Panei, Massimo organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research – sequence: 12 givenname: Pierluigi surname: Bove fullname: Bove, Pierluigi organization: Department of Urology, “San Carlo di Nancy” Hospital – GVM Care and Research, Urology Unit, Department of Surgery, Tor Vergata University of Rome |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35151280$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k8tu1TAQhiNURC_wAiyQJTZFaortJE7CAqlUXI5UBIvuLceZnOPKsYOdVBweiofgmXgAJuf0LlRlkdH4_7_xWDP7yY7zDpLkJaPHjFXibWS8qvOUcp5SWpcYPUn2WF6ylOc13bkT7yb7MV5QysqqEM-S3axgBZrpXvL3fAUEus5opdfEd0SROA2Dj2b0YU0aFaEl3pHvK3De9kYbjDOiXEs--Ag_jSWHX40elUXln99vCJ5r78bg7UwzIZhRjeYSSFz3w-j7OCsGTIEbI5lcC2HpjVuScTVZM_VkBgUCbtIWUIa1kTMEH5ED7-b7odpCqhEA4YgEvIvvzS9oj64r2zn2AziENWCPyLBCKFksFiSOU7t-njztlI3w4up_kJx_-nh--iU9-_Z5cXpylmpByzEVRSeytmV5UeRtRXmmcia01i1tlG6ErouuKssGaEFFlrNS5yqrGpQyAYpBdpAsttjWqws5BNOrsJZeGblJ-LCUKowG-5QdVTUHXmeAgK5jtW451aXoeFsKxXJkvd-yhqnpoZ2bD8reg94_cWYll_5SVlVOi7xGwOEVIPgfE8RR9iZqsFY58FOUXPBK1BUv5lqvH0gv_BQcvhSqMloUNOP1rWqpsAHjOo919QyVJ6LOBI4mZ6g6_o8KvxZwmHCeO4P5e4ZXdxu96fB6ZFHAtwKNMxEDdDcSRuW8F3K7FxL3Qm72Qs6m6oFJb-Zynhdl7OPWbGuNWMctIdy-xiOuf4RnJmI |
| CitedBy_id | crossref_primary_10_1007_s00345_024_04901_w |
| Cites_doi | 10.1002/ptr.2093 10.1001/jama.285.15.1987 10.1016/j.fct.2012.02.097 10.23736/S0393-2249.17.02834-X 10.1371/journal.pone.0157097 10.1128/jcm.9.5.596-597.1979 10.1007/s00345-013-1054-y 10.1007/s00345-014-1260-2 10.4081/aiua.2019.4.251 10.1016/0140-6736(91)90543-x 10.1007/s00345-016-1922-3 10.1016/j.acuro.2016.06.010 10.1007/s00345-015-1735-9 10.1097/MD.0000000000013360 10.3390/jcm9051412 10.1038/nature11556 10.1007/s00345-021-03663-z 10.1007/s00345-019-02945-x 10.1016/j.eururo.2007.10.059 10.1590/S1677-5538.IBJU.2021.0726 10.1016/j.amjmed.2008.01.043 10.1097/JU.0000000000001638 10.2174/092986706779010333 10.1016/j.eururo.2013.03.004 10.1097/01.sla.0000133083.54934.ae 10.1016/j.eururo.2006.04.003 10.1111/j.1476-5381.2010.01020.x |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12894-022-00974-0 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ (Directory of Open Access Journals) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central Database Suite (ProQuest) url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2490 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_f0a92e293e8b4ff19cd20c76f2d76a14 PMC8840549 A693689421 35151280 10_1186_s12894_022_00974_0 |
| Genre | Randomized Controlled Trial Clinical Trial, Phase III Journal Article |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACIHN ACPRK ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7QP 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c607t-65f63dd14554d8023a416cccd0bacb6c95f877be05063417c4a38b4d816ea1e3 |
| IEDL.DBID | M48 |
| ISSN | 1471-2490 |
| IngestDate | Wed Aug 27 00:49:24 EDT 2025 Thu Aug 21 18:31:41 EDT 2025 Fri Sep 05 04:44:02 EDT 2025 Fri Jul 25 07:07:24 EDT 2025 Tue Jun 17 21:05:47 EDT 2025 Tue Jun 10 20:36:38 EDT 2025 Mon Jul 21 05:45:45 EDT 2025 Thu Apr 24 23:03:30 EDT 2025 Tue Jul 01 01:02:46 EDT 2025 Sat Sep 06 07:22:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | ThuLEP Benign prostatic hyperplasia Urinary tract infections BPH LUTS Laser enucleation |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-65f63dd14554d8023a416cccd0bacb6c95f877be05063417c4a38b4d816ea1e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12894-022-00974-0 |
| PMID | 35151280 |
| PQID | 2630550329 |
| PQPubID | 42551 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f0a92e293e8b4ff19cd20c76f2d76a14 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8840549 proquest_miscellaneous_2628698254 proquest_journals_2630550329 gale_infotracmisc_A693689421 gale_infotracacademiconefile_A693689421 pubmed_primary_35151280 crossref_primary_10_1186_s12894_022_00974_0 crossref_citationtrail_10_1186_s12894_022_00974_0 springer_journals_10_1186_s12894_022_00974_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-12 |
| PublicationDateYYYYMMDD | 2022-02-12 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC urology |
| PublicationTitleAbbrev | BMC Urol |
| PublicationTitleAlternate | BMC Urol |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | U Siemoneit (974_CR25) 2011; 162 C Netsch (974_CR15) 2014; 32 974_CR22 974_CR23 D Poeckel (974_CR24) 2006; 13 E Baten (974_CR31) 2021; 205 WM Garraway (974_CR2) 1991; 338 I Vavassori (974_CR14) 2008; 53 G Bozzini (974_CR8) 2017; 41 Y Lin (974_CR10) 2016; 34 R Naspro (974_CR13) 2006; 50 D Moher (974_CR16) 2001; 285 A Tepeler (974_CR19) 2014; 32 M Oelke (974_CR3) 2013; 64 974_CR7 Y Naito (974_CR28) 2007; 21 JY Teoh (974_CR12) 2021 R Gleckman (974_CR21) 1979; 9 R Naspro (974_CR4) 2017; 69 J Zhang (974_CR11) 2020; 38 P Ristivojević (974_CR27) 2016; 11 BC Taylor (974_CR30) 2008; 121 TRW Herrmann (974_CR5) 2016; 34 TRW Herrmann (974_CR6) 2020; 9 SC Landis (974_CR17) 2012; 490 CG Roehrborn (974_CR1) 2005; 7 JC Silva (974_CR26) 2012; 50 R Bertolo (974_CR18) 2022 F Sun (974_CR9) 2018; 97 M Sibona (974_CR29) 2020; 91 D Dindo (974_CR20) 2004; 240 |
| References_xml | – volume: 21 start-page: 452 issue: 5 year: 2007 ident: 974_CR28 publication-title: Phytother Res doi: 10.1002/ptr.2093 – volume: 285 start-page: 1987 issue: 15 year: 2001 ident: 974_CR16 publication-title: JAMA. doi: 10.1001/jama.285.15.1987 – ident: 974_CR7 – volume: 50 start-page: 1790 issue: 5 year: 2012 ident: 974_CR26 publication-title: Food Chem Toxicol doi: 10.1016/j.fct.2012.02.097 – volume: 69 start-page: 446 issue: 5 year: 2017 ident: 974_CR4 publication-title: Minerva Urol Nefrol doi: 10.23736/S0393-2249.17.02834-X – volume: 11 start-page: e0157097 issue: 6 year: 2016 ident: 974_CR27 publication-title: PLoS ONE doi: 10.1371/journal.pone.0157097 – volume: 9 start-page: 596 issue: 5 year: 1979 ident: 974_CR21 publication-title: J Clin Microbiol doi: 10.1128/jcm.9.5.596-597.1979 – ident: 974_CR22 – volume: 32 start-page: 131 issue: 1 year: 2014 ident: 974_CR19 publication-title: World J Urol doi: 10.1007/s00345-013-1054-y – volume: 32 start-page: 1551 issue: 6 year: 2014 ident: 974_CR15 publication-title: World J Urol doi: 10.1007/s00345-014-1260-2 – volume: 91 start-page: 251 issue: 4 year: 2020 ident: 974_CR29 publication-title: Arch Ital Urol Androl doi: 10.4081/aiua.2019.4.251 – volume: 338 start-page: 469 issue: 8765 year: 1991 ident: 974_CR2 publication-title: Lancet doi: 10.1016/0140-6736(91)90543-x – volume: 34 start-page: 1353 issue: 10 year: 2016 ident: 974_CR5 publication-title: World J Urol doi: 10.1007/s00345-016-1922-3 – volume: 41 start-page: 309 issue: 5 year: 2017 ident: 974_CR8 publication-title: Actas Urol Esp doi: 10.1016/j.acuro.2016.06.010 – volume: 34 start-page: 1207 issue: 9 year: 2016 ident: 974_CR10 publication-title: World J Urol doi: 10.1007/s00345-015-1735-9 – volume: 97 start-page: e13360 issue: 51 year: 2018 ident: 974_CR9 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000013360 – volume: 9 start-page: 1412 issue: 5 year: 2020 ident: 974_CR6 publication-title: J Clin Med doi: 10.3390/jcm9051412 – volume: 490 start-page: 187 issue: 7419 year: 2012 ident: 974_CR17 publication-title: Nature doi: 10.1038/nature11556 – year: 2021 ident: 974_CR12 publication-title: World J Urol doi: 10.1007/s00345-021-03663-z – volume: 38 start-page: 1555 issue: 6 year: 2020 ident: 974_CR11 publication-title: World J Urol doi: 10.1007/s00345-019-02945-x – volume: 53 start-page: 599 issue: 3 year: 2008 ident: 974_CR14 publication-title: Eur Urol doi: 10.1016/j.eururo.2007.10.059 – ident: 974_CR23 – year: 2022 ident: 974_CR18 publication-title: Int Braz J Urol doi: 10.1590/S1677-5538.IBJU.2021.0726 – volume: 121 start-page: 444 issue: 5 year: 2008 ident: 974_CR30 publication-title: Am J Med doi: 10.1016/j.amjmed.2008.01.043 – volume: 205 start-page: 1748 issue: 6 year: 2021 ident: 974_CR31 publication-title: J Urol doi: 10.1097/JU.0000000000001638 – volume: 13 start-page: 3359 issue: 28 year: 2006 ident: 974_CR24 publication-title: Curr Med Chem doi: 10.2174/092986706779010333 – volume: 64 start-page: 118 issue: 1 year: 2013 ident: 974_CR3 publication-title: Eur Urol doi: 10.1016/j.eururo.2013.03.004 – volume: 240 start-page: 205 issue: 2 year: 2004 ident: 974_CR20 publication-title: Ann Surg doi: 10.1097/01.sla.0000133083.54934.ae – volume: 50 start-page: 563 issue: 3 year: 2006 ident: 974_CR13 publication-title: Eur Urol doi: 10.1016/j.eururo.2006.04.003 – volume: 162 start-page: 147 issue: 1 year: 2011 ident: 974_CR25 publication-title: Br J Pharmacol doi: 10.1111/j.1476-5381.2010.01020.x – volume: 7 start-page: S3 issue: Suppl 9 year: 2005 ident: 974_CR1 publication-title: Rev Urol |
| SSID | ssj0017856 |
| Score | 2.2564971 |
| Snippet | Background
Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence,... Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked... Background Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence,... Abstract Background Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 19 |
| SubjectTerms | Aged Analgesics Analysis Benign prostatic hyperplasia BPH Catheters Clinical trials Endoscopy Enucleation Health aspects Humans Internal Medicine Intubation Irritation Labels Laser enucleation Lasers Lasers in surgery Lasers, Solid-State - adverse effects Lasers, Solid-State - therapeutic use Lower Urinary Tract Symptoms - drug therapy Lower Urinary Tract Symptoms - etiology Lower Urinary Tract Symptoms - prevention & control LUTS Male Medical research Medicine Medicine & Public Health Medicine, Experimental Middle Aged Pain Patients Postoperative Complications - drug therapy Postoperative Complications - prevention & control Prospective Studies Prostate Prostate cancer Prostatic Hyperplasia - complications Prostatic Hyperplasia - surgery Quality of life Statistical analysis Suppositories ThuLEP Thulium - adverse effects Thulium - therapeutic use Tumors Urinalysis Urinary incontinence Urinary tract Urinary tract diseases Urinary tract infections Urine Urogenital system Urological Agents - therapeutic use Urology Variables |
| SummonAdditionalLinks | – databaseName: DOAJ (Directory of Open Access Journals) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4p-FgoyEBIiNmtiJ43BrEVWLtKiHIvUWObbDRsomqySLWB6Kh-CZeABmnGRpioALt2g9dmzn8_ys7W8Iea5UzpJYcY_jcoMAIvCyhAlPcp2EYDJYbjBQXHwQJx_D9xfRxaVUX3gmrKcH7ifuIPdVwiwYJSuzMM-DRBvm61jkzMRCuRTWzE_8MZga9g9iGYnxiowUBy1oYaTAhcALLy7A08QMObb-33XyJaN09cDklV1TZ4yOb5GbgxdJD_ve3ybXbHWHXF8M--R3yQ_4-tQiO4TSW1rnVNF2s3YHtOpmS9F0GVpX9Gxpq7pcYS16xqmqDD2qW_ulKOnLRaE7vGRpv397RaF8ONSOrRVN46i9P1vablfrrl61KDFwtLYUL6Y1n2roOu2Wm7LYrCg21FBbIX2yAwO2s8YrJ-DsvsH-gXRpPRy7beYUTKipV8VXa-bjm0t8xmxf0FhmyzldL6FRenp6Sh1J7j1yfvzu_O2JN-R38LTw484TUS64MUiVHhokolPgHWqtjZ8pnQmdRLmM48z6EfhRYRDrUHEAgZGBsCqw_D7Zq-rKPiRUQV0JjiCDGmGScWmyGOJQDt4PAMWPZyQYv3aqB-5zTMFRpi4GkiLtEZICQlKHkNSfkde7Ouue-eOv0kcIop0ksna7HwDL6YDl9F9YnpEXCMEUdQt0DyDSX5GAQSJLV3ooEi7gxSyYkf2JJOgEPS0eQZwOOqlNmUB2N5-zZEae7YqxJp6zq2y9QRkmRYL_GszIgx7zuyHxCL1DCUONJ6thMuZpSVUsHWO5lBAXhPDe-bhufnXrz3P66H_M6WNyg7l1jzl89sle12zsE_Aju-ypUxk_ASMacVA priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELdgSIgXxH8CAxkJCRCNljipk_CCNsS0IhXtYUh9sxzbWSOlSUhSRPlQfAg-Ex-AOzfpyBB7i-qz42vO98f2_Y6Ql1JmLIlk4Aa43CCA8N00YdyNA5WEYDJYpjFQnH_mJ1_CT4vpot9wa_trlYNOtIpaVwr3yA8YR2wqL2DJ-_qri1Wj8HS1L6FxndzwwRPB0g3RYhdwYeF5PiTKxPygBV2MQLgQfmH6AjyNjJHF7P9XM_9lmi5fm7x0dmpN0vEdcrv3Jenh9uPfJddMeY_cnPen5ffJb5ABahAjQqoNrTIqabuu7TWtqtlQNGCaViU9XZqyKlbYi54GVJaaHlWt-Z4X9PU8Vx2mWppfP99QaO-vtuNoedNYgO9vhrabVd1VqxYpeqTWlmJ6WnNewdRpt1wX-XpFcaCGmhJBlK1I4Dg1Jp6Ay_sO5wfUhXGRd9NMKBhSXa3yH0ZPhjcX-Iw1v2Cw1BQTWi9hUDqbzaiFyn1Azo4_nn04cfsqD67iXtS5fJrxQGsETA81wtFJ8BGVUtpLpUq5SqZZHEWp8abgTYV-pEIZxCmQ-txI3wQPyV5ZleYxoRL6xuAOMugRJmkQ6zSCaDQAH4hnzIsc4g9fW6geAR0LcRTCRkIxF1sJESAhwkqI8Bzydten3uJ_XEl9hEK0o0TsbvtD1ZyLXhWIzJMJM-BmGWAjy_xEaeapCKaoIy790CGvUAQFahiYHojINlECmESsLnHIk4DDi5nvkP0RJWgGNW4ehFj0mqkVF-vIIS92zdgTb9uVplojDYt5gnsHDnm0lfkdS8EUfcQYWI1Gq2HE87ilzJcWtzyOIToI4b2TYd1cTOv__-mTq7l4Sm4xu6KxRs8-2euatXkGfmKXPrfK4A-5NGg8 priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3ditQwFA66gngj_ltdJYKg4hTbtE1T73YHl11hZC9W2LuQJqlT6LRD2xHHh_IhfCYfwHMynXG7_oB3ZXJOmjM5OT9NzhdCnitVsCxVkR_hcoMEIvTzjHFfRDqLwWWwwmCiOPvAjz_G78-T8wEmB2thLu7fh4K_6cB-IngtpExYcgBPV8m1BAwvavOUT3c7BqlI-LYo5o98I8fj8Pl_t8IX3NDlI5KX9kmd-zm6RW4OcSM92Ez0bXLF1nfI9dmwM36X_ID5phbxIJRe06aginarpTuS1bRris7K0Kamp3NbN9UCuehpRFVt6GHT2S9lRV_OSt1jWaX9_u0VhfbhGDv2VratA_P-bGm3Xiz7ZtEhxYDK2lEsRWs_NTB02s9XVblaUOyopbZGwGQ3_djPEotMILx9i-MD6sr6KLttJxScpmkW5VdrJts3V_iM93tBZ7mtJnQ5h07pyckJdbC498jZ0buz6bE_3Ojgax6kvc-TgkfGIDh6bBB6TkE8qLU2Qa50znWWFCJNcxskEDnFYapjFYkcSENuVWij-2Svbmr7kFAFvAJCPwYccZZHwuQpZJ4RxDu8YEHqkXA721IPaOd46UYlXdYjuNxoiAQNkU5DZOCR1zue5Qbr45_Uh6hEO0rE6XY_gPrKYdnLIlAZsxBSWRCjKMJMGxboFIZoUq7C2CMvUAUlWhMYHqjIpigChERcLnnAs4jDi1nokf0RJVgBPW7eKrEcrFAnGUc8tyBimUee7ZqRE0_W1bZZIQ0TPMPvBB55sNH5nUhRgvGgAFHT0WoYyTxuqcu5wygXAjKBGN472a6bX8P6-3_66P_IH5MbzK1wvJ9nn-z17co-gRixz5864_AT4exhLQ priority: 102 providerName: Springer Nature |
| Title | The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study |
| URI | https://link.springer.com/article/10.1186/s12894-022-00974-0 https://www.ncbi.nlm.nih.gov/pubmed/35151280 https://www.proquest.com/docview/2630550329 https://www.proquest.com/docview/2628698254 https://pubmed.ncbi.nlm.nih.gov/PMC8840549 https://doaj.org/article/f0a92e293e8b4ff19cd20c76f2d76a14 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9swEBZ9gdIvY-_z1gUNBttYvPlVsgdjNKWlGaSE0kLYFyPLcmNw7MxORrMftR-x37QfsDvFTpuu24d9CY51pxf7Tndn6R4R8lKI1Am5cE0X1Q0CCNuMQ4eZgStDD0yGkyYYKA5O2PG593nkjzZIe9xR8wDrW0M7PE_qvMrfXX5dfAKF_6gVPmDva5hjEeAWwipMS4CrTbKt14twK593tarAA5-1iTO38u2SHddHG4gokdfslIbz_3PSvma1bu6ovLGsqq3V0V1yp3Ez6f5SLu6RDVXcJzuDZiH9AfkF4kEVwkcIuaBlSgWt51O9g6usFhRtW0LLgg7HqijzCXLRoUtFkdBeWavLLKevB5mcYRam-vnjDYXyZtc71pZVlcb-_qZovZhMZ-WkRooGxLWmmLlWXZTQdTobz_NsPqFYUUVVgfjKWlqwninmpIA3_AH7B9S5MnHsqupSsLFJOcm-q6TbtpzjNb4-qCxWeZdOx1Ap7ff7VKPoPiRnR4dnB8dmcwCEKZnFZybzU-YmCWKpewki1QlwH6WUiRULGTMZ-mnAeawsHxwtz-bSE24QA6nNlLCV-4hsFWWhnhAqgDcAT9EBDi-M3SCJOQSqLrhHLHUsbhC7fduRbMDR8YyOPNJBUsCipbBEICyRFpbIMsjbFc90CQ3yT-oeCtGKEmG99Y2yuoiaWSJKLRE6CjwwBcNIUzuUiWNJDl1MOBO2Z5BXKIIRqgN0D0RkmUMBg0QYr2ifhS6Dhh3bIHtrlDBpyPXiVoijVucihyH8m-U6oUFerIqREzfiFaqcI40TsBA_Kxjk8VLmV0NqVccgfE0b1sa8XlJkYw1pHgQQOHjQbrfVm6tu_f2ZPv3vhp6RXUfrPZ7ss0e2ZtVcPQfvchZ3yCYf8Q7Z7h2eDE_h3wE76OgvNR09mcDvae_Lb7O6fiw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGJgEviP8UBhgJBIhGS5zUSZAmtMGmla3ThDppb5ZjO2ulNClJC5QPxTfghc_EB-DOTTo6xN72FtVnx9ec74_t-x0hz6VMWRxK3_FxuUEA4TlJzLgT-SoOwGSwVGOg2Dvke8fBx5POyQr52eTC4LXKRidaRa0LhXvkG4wjNpXrs_jd-LODVaPwdLUpoSHr0gp600KM1Ykd-2b2FUK4arP7Ab73C8Z2d_rv95y6yoCjuBtOHN5Jua81AnYHGuHQJPgoSintJlIlXMWdNArDxLgdsOaBF6pA-lECpB430jM-DHuFrAW4f7JK1rZ3Do8-LY4xwqjDm0ydiG9UYAwQiRfiP8yfgKcla2iLBvxrGv6yjefvbZ47vLU2cfcmuVE7s3RrLn23yIrJb5Orvfq4_g75DUJIDYJUSDWjRUolraZje0-sKGcULaimRU6PBiYvshH2okc-lbmm20Vlvg0z-qo3VBPM9TS_frym0F7frcfRhmVpEca_GFrNRuNJMaqQooaKrSjmx5WnBUydTgbTbDgdURyopCZHFGcrkzjOGDNfwOd-i_MD6sw4yLsp2xQsuS5Gw-9Gt5s3Z_iMRcdgsMRkbToewKC02-1Si9V7l_QvQwDukdW8yM0DQiX0jcAfZdAjiBM_0kkI4bAPThhPmRu2iNd8baFqCHasBJIJG4pFXMwlRICECCshwm2RN4s-4zkAyYXU2yhEC0oED7c_FOWpqHWRSF0ZMwN-ngE20tSLlWauCmGKOuTSC1rkJYqgQBUH0wMRmWdqAJMIFia2eOxzeDHzWmR9iRJUk1puboRY1KqxEmcLuUWeLZqxJ173y00xRRoW8Rg3L1rk_lzmFyz5HXRSI2A1XFoNSzwvt-TDgQVOjyIITwJ4b7tZN2fT-v9_-vBiLp6Sa3v93oE46B7uPyLXmV3dWDBonaxOyql5DE7rJHlSqwZKxCUroz_aZ6r6 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1fb9MwELdgSBMviP8EBhgJCRCNlsSpk_C2FaYV6NSHIe3NcmxnjZQmVZIiyofiQ_CZ-ADcOWlZxx-Jt6i-s33N-XwX3_1MyHMpsyCJJHMZLjcIIHw3TQLuxkwlIWwZQaYxUJyc8ONP4fuz4dmFKn6b7b4-kuxqGhClqWz3FzrrlnjM9xuwqghpC4EUFiLA01VyDbG6MKlvxEebc4QoHvJ1qcwf-ba2I4va_7ttvrA5XU6cvHR6ajelo5vkRu9N0oPu9d8iV0x5m-xO-vPyO-QHaAE1iBIh1YpWGZW0WS5solZVryhuYZpWJZ3OTFkVc-SiU0Zlqelh1ZgveUFfTnLVYrGl-f7tFYX2Prkde8vr2kJ8fza0Wc0XbTVvkKLHam0oFqjV5xVMnbazZZEv5xQ7qqkpEUbZKgX2s8DSE3B63-D8gLowLspu6gGFrVRX8_yr0YP1yAU-461f0FlqigFdzKBTOh6PqQXLvUtOj96djo7d_p4HV3Eval0-zDjTGiHTQ42AdBK8RKWU9lKpUq6SYRZHUWq8IfhToR-pULI4BVKfG-kbdo_slFVpHhAqgTcGhzAAjjBJWazTCOJRBl4QzwIvcoi_fttC9RjoeBVHIWwsFHPRaYgADRFWQ4TnkNcbnkWHAPJP6kNUog0lonfbH6r6XPTGQGSeTAIDjpYBMbLMT5QOPBXBFHXEpR865AWqoEAbA9MDFelKJUBIROsSBzxhHAYOfIfsbVGCbVDbzWslFr1takTAEeXNY0HikGebZuTEfLvSVEukCWKe4NcDh9zvdH4jEhuilxiDqNHWatiSebulzGcWuTyOIT4IYdzBet38mtbf_9OH_0f-lOxO3x6Jj-OTD4_I9cAudrzAZ4_stPXSPAYnsk2fWDvxE5MdbGw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+efficacy+of+a+suppository+based+on+Phenolmicin+P3+and+Bosexil+%28Mictalase%C2%AE%29+in+control+of+irritative+symptoms+in+patients+undergoing+thulium+laser+enucleation+of+prostate%3A+a+single-center%2C+randomized%2C+controlled%2C+open+label%2C+phase+III+study&rft.jtitle=BMC+urology&rft.au=Bertolo%2C+Riccardo&rft.au=Cipriani%2C+Chiara&rft.au=Vittori%2C+Matteo&rft.au=Carilli%2C+Marco&rft.date=2022-02-12&rft.pub=BioMed+Central&rft.eissn=1471-2490&rft.volume=22&rft_id=info:doi/10.1186%2Fs12894-022-00974-0&rft_id=info%3Apmid%2F35151280&rft.externalDocID=PMC8840549 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2490&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2490&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2490&client=summon |